Abstract 1496P
Background
Since the recruitment and polarization of TAMs are regulated by CSF-1R/CSF-1, the expression levels of these factors may be indicative of TAM physiology and correlated with antitumoral immunity and response to therapy. This study aimed to investigate the influence of CSF-1R/CSF-1 activation levels on tumor response in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line immune checkpoint inhibitor (ICI) therapy.
Methods
This bicentric study included a prospective cohort of 88 patients with advanced NSCLC treated with ICIs as first-line therapy. Plasma levels of CSF-1 were assessed by ELISA. Peripheral blood mononuclear cells were used both for immunomodulatory assays and to produce macrophages through CSF-1 treatment. To assess the mechanism of CSF-1-mediated suppression of immunotherapy, Isolated PBMC, activated with phytohemagglutinin (PHA) with or without pembrolizumab (20 nM), were cultured alone, or in the presence of macrophages or on an established NSCLC monolayer. INFγ levels and CD8+ proliferation/activation were assessed through ELISA assay and flow cytometry respectively.
Results
Plasma levels of CSF-1 were found to be higher in patients resistant to ICI therapy (8898 vs. 14031 pg/mL, p < 0.001). Higher levels of CSF-1 were associated with poor therapy response (RR = 7,944; p = 0.013), disease progression (RR = 8.556; p < 0.001), and shorter survivals (PFS, 50 days vs. 305 days; p < 0.001; OS, 248 days vs. 1369 days, p < 0.01). In vitro, recombinant CSF-1 inhibited CD8+ activation and interferon gamma (INFγ) production that was induced by PHA and Pembrolizumab. The use of Pexidartinib (PLX-3397), a CSF-1R inhibitor, reversed the effects of CSF-1 by restoring lymphocyte activation. However, these effects were dependent on the presence of monocytes/macrophages, suggesting that the immune suppression mediated by CSF-1 was an indirect effect resulting from the stimulation of monocytes that promote their differentiation into macrophages.
Conclusions
Our study suggests that plasma levels of CSF-1 could serve as a useful predictive biomarker for resistance to ICIs, while targeting the CSF-1/CSF-1R signaling pathway could potentially overcome resistance to ICIs in patients with NSCLC.
Clinical trial identification
Legal entity responsible for the study
University of Paris Saclay, UVSQ.
Funding
Legs Poix Subvention (2018).
Disclosure
E. Giroux-Leprieur: Financial Interests, Personal, Advisory Role: Amgen, AstraZeneca, Ipsen, Janssen, Lilly, MSD, Novartis, Pfizer, Takeda, Sanofi. All other authors have declared no conflicts of interest.
Resources from the same session
1535P - Paclitaxel + ramucirumab versus paclitaxel alone in patients with squamous-cell carcinoma of the oesophagus, refractory or intolerant to combination therapy with fluoropyrimidine and platinum-based drugs: Final results from the randomized phase II IKF-S627/RAMOS trial of the AIO
Presenter: Magdalena Scheck
Session: Poster session 21
1536P - HERIZON: A phase II study of HER-Vaxx (IMU-131), a HER2-targeting peptide vaccine plus standard of care chemotherapy in patients with HER2+ advanced stomach cancer - Dose-dependent anti-cancer antibodies correlating with improved clinical outcome
Presenter: Joshua Tobias
Session: Poster session 21
1537P - A phase I study of pevonedistat plus capeOX in patients with advanced gastric cancer refractory to platinum (NCCH-1811)
Presenter: Daisuke Takahari
Session: Poster session 21
1540P - Tislelizumab combined with neoadjuvant chemoradiotherapy for resectable locally advanced oesophageal squamous cell carcinoma: A prospective, phase II clinical study
Presenter: Yi Zhang
Session: Poster session 21
1541P - Neoadjuvant therapy of camrelizumab combined with chemotherapy in patients (pts) with resectable esophageal squamous cell cancer (ESCC)
Presenter: Yinjun Dong
Session: Poster session 21
1542P - Updated results of a phase II clinical trial: Paclitaxel and carboplatin plus PD-1 blockades combined with anlotinib as first-line treatment for advanced oesophageal cancer
Presenter: Mingfang Xu
Session: Poster session 21